{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["LoRusso PM"],"funding":["Stand Up To Cancer","NCATS NIH HHS","Gateway for Cancer Research","NCI NIH HHS"],"pagination":["e0248097"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8026051"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(4)"],"pubmed_abstract":["Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAFV600wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included "],"journal":["PloS one"],"pubmed_title":["Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial."],"pmcid":["PMC8026051"],"funding_grant_id":["G-12-500","P30 CA008748","UL1 TR001863","SU2C-AACR-DT0612"],"pubmed_authors":["Sekulic A","Halperin R","Lao C","Byron SA","DeVeaux M","Kiefer JA","Calvert VS","Izatt T","Nasser S","Keats J","Schork N","Eder JP","Schmidt J","Sekar S","Manica B","Craig DW","Hendricks WPD","Bryce AH","Cowey CL","Markovic SN","Fecher LA","Fox L","Vogelzang NJ","Joseph RW","Durecki D","Petricoin EF","Perlmutter J","Gorman M","Legendre C","Enriquez D","LoRusso PM","Zelterman D","Zismann V","Aldrich J","Trent JM","Liang WS","Pilat MJ","Naveed F","Sivaprakasam K","Basu GD","Carpten J","Weise A","Sosman JA","Boerner SA","Adkins J","Solit DB","Tassone E"],"additional_accession":[]},"is_claimable":false,"name":"Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial.","description":"Although combination BRAF and MEK inhibitors are highly effective for the 40-50% of cutaneous metastatic melanomas harboring BRAFV600 mutations, targeted agents have been ineffective for BRAFV600wild-type (wt) metastatic melanomas. The SU2C Genomics-Enabled Medicine for Melanoma Trial utilized a Simon two-stage optimal design to assess whether comprehensive genomic profiling improves selection of molecular-based therapies for BRAFV600wt metastatic melanoma patients who had progressed on standard-of-care therapy, which may include immunotherapy. Of the response-evaluable patients, binimetinib was selected for 20 patients randomized to the genomics-enabled arm, and nine were treated on the alternate treatment arm. Response rates for 27 patients treated with targeted recommendations included ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-04-29T00:20:27.921Z","creation":"2022-02-09T15:59:30.727Z"},"accession":"S-EPMC8026051","cross_references":{"pubmed":["33826614"],"doi":["10.1371/journal.pone.0248097"]}}